Previous 10 | Next 10 |
home / stock / lobef / lobef news
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences , the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Co...
Lobe Sciences (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is biotechnology company entering clinical stage development this year and is focused on transforming psychedelic medicine to benefit patients of all ages. Lobe is engaged in research and development using psychedelic and n...
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022. The Company'...
Vancouver, British Columbia--(Newsfile Corp. - March 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") announced today that Philip Young, CEO, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-V...
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") today announced that Philip Young, CEO and Director, will present at the MONEYSHOW VIRTUAL EXPO, March 23 rd at 11:30AM EST. The presentatio...
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (the " Acquiror ") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 22, 2022 and February 23, 2022, it sold a total of 4...
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Lobe Sciences Ltd (CSE: LOBE) (OTCQB: LOBEF) today announced that Philip Young CEO will be attending the Q1 Virtual Investor Summit. During this presentation Lobe’s CEO Philip Young will provide highlights of the Co...
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Lobe Sciences Ltd. (the " Acquiror ") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 15, 2022, it sold 5,800,000 common shares in the capital of Ionic Brands Corp. (t...
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2022) - Lobe Sciences Ltd. (the " Acquiror ") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 11, 2022, it sold 8,000,000 common shares in the capital of Ionic Brands Corp. (t...
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Lobe Sciences Ltd. (the " Acquiror ") announces, pursuant to the early warning requirements of Canadian securities legislation, that on February 3, 2022, it acquired 47,065,647 common shares in the capital of Ionic Brands Corp....
News, Short Squeeze, Breakout and More Instantly...
Company Exploring Alternative Value Creation Opportunities Convertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding Strategy Annual General Meeting Set for 22 July 2024 Lobe Sciences Ltd. (O...
Accomplished Investor and Serial Entrepreneur Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Wesley Ramjeet has agreed to join its Board of Di...
Providing a Proven Track Record of Driving Growth and Innovation Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. ha...